Patients with advanced Hodgkin lymphoma treated with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) did not show a progression-free survival (PFS) when compared with patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), according to a study published in the Journal of Clinical Oncology.1

Investigators conducted a post-hoc analysis of the HD2000 trial, which compared 6 cycles of ABVD, 4 escalated plus 2 standard cycles of BEACOPP, and 6 cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced stage Hodgkin lymphoma.

The study included 295 evaluable patients. After a median follow-up of 10 years, results showed that the 10-year PFS was highest in the CEC arm (76%), followed by BEACOPP (75%), and ABVD arm (69%). Overall survival results were 86%, 84%, and 85%, respectively.

Continue Reading

Out of the 13 second malignancies reported, 1 occurred in the ABVD arm and 6 occurred in each the BEACOPP and CEC arms.  

The authors concluded that although patients treated with ABVD, BEACOPP, or CEC had similar overall survival results, longer follow-up did not show a PFS advantage with BEACOPP when compared with ABVD. These results were attributed to higher mortality rates due to second malignancies after treatment with BEACOPP and CEC.


  1. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi [published online ahead of print on December 28, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.4817.